Current Research Studies - Cancer

For additional information on the enrolling clinical research studies listed below, or to inquire about enrollment, contact the individual listed for the study.

For general inquiries about other clinical research being conducted at OSF HealthCare locations, contact us at osf.clinicalresearch@osfhealthcare.org.

Breast

  • The ABC Trial: A randomized phase III double blinded placebo-controlled trial of aspirin as adjuvant therapy for node-positive, HER2 negative breast cancer.

  • Summary: This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) breast cancer after chemotherapy, surgery, and/or radiation therapy. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. It is also being studied in cancer prevention. Giving aspirin may reduce the rate of cancer recurrence in patients with breast cancer.

    Investigator: Shylendra Sreenivasappa, MD

    Location: OSF HealthCare Saint Anthony Medical Center, Center for Cancer Care, Rockford, Illinois

    ClinicalTrials.gov: 

    Contact: Karen Blatter, 815-227-2676,

  • COMET: Comparison of Operative to Monitoring and Endocrine Therapy Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial

  • Summary: This study looks at the risks and benefits of active surveillance (AS) compared to guideline concordant care (GCC) in the setting of a pragmatic prospective randomized trial for low risk DCIS. Our overarching hypothesis is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AS approach does not yield inferior cancer or quality of life outcomes compared to GCC.

    Investigator: Shylendra Sreenivasappa, MD

    Location: OSF HealthCare Saint Anthony Medical Center, Center for Cancer Care, Rockford, Illinois

    ClinicalTrials.gov:  NCT02926911

    Contact: Karen Blatter, 815-227-2676,

Colorectal

  • PACES: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac

  • Summary: The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.

    Investigator: Shylendra Sreenivasappa, MD

    Location: OSF HealthCare Saint Anthony Medical Center, Center for Cancer Care, Rockford, Illinois

    ClinicalTrials.gov:  NCT01349881

    Contact: Karen Blatter, 815-227-2676,

Lung

  • ALCHEMIST Screening: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

  • Summary: This phase III ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

    Investigator: Shylendra Sreenivasappa, MD

    Location: OSF HealthCare Saint Anthony Medical Center, Center for Cancer Care, Rockford, Illinois

    ClinicalTrials.gov:  NCT02194738

    Contact: Karen Blatter, 815-227-2676,

  • ALCHEMIST ALK: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer:  Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Pro

  • Summary: This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.

    Investigator: Shylendra Sreenivasappa, MD

    Location: OSF HealthCare Saint Anthony Medical Center, Center for Cancer Care, Rockford, Illinois

    ClinicalTrials.gov:  NCT02201992

    Contact: Karen Blatter, 815-227-2676,

  • ALCHEMIST EGFR: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

  • Summary: This phase III ALCHEMIST trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

    Investigator: Shylendra Sreenivasappa, MD

    Location: OSF HealthCare Saint Anthony Medical Center, Center for Cancer Care, Rockford, Illinois

    ClinicalTrials.gov:  NCT02193282

    Contact: Karen Blatter, 815-227-2676,

  • Lung-MAP Screening: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer

  • Summary: This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

    Investigator: Shylendra Sreenivasappa, MD

    Location: OSF HealthCare Saint Anthony Medical Center, Center for Cancer Care, Rockford, Illinois

    ClinicalTrials.gov:  NCT03851445

    Contact: Karen Blatter, 815-227-2676,

  • Lung-MAP Sub-Study: A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer

  • Summary: This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Investigator: Shylendra Sreenivasappa, MD

    Location: OSF HealthCare Saint Anthony Medical Center, Center for Cancer Care, Rockford, Illinois

    ClinicalTrials.gov:  NCT03845296

    Contact: Karen Blatter, 815-227-2676,

  • Lung-MAP Non-Matched Sub-Study: A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

  • Summary: This phase II Lung-MAP non-Match treatment trial studies how well ramucirumab and pembrolizumab work versus standard of care in treating patients with non-small cell lung cancer that is stage IV or has come back. Immunotherapy with monoclonal antibodies, such as ramucirumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in standard of care chemotherapy for non-small cell lung cancer, such as docetaxel, gemcitabine hydrochloride, and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ramucirumab and pembrolizumab together may work better in treating patients with non-small lung cancer compared to standard of care.

    Investigator: Shylendra Sreenivasappa, MD

    Location: OSF HealthCare Saint Anthony Medical Center, Center for Cancer Care, Rockford, Illinois

    ClinicalTrials.gov:  NCT03971474

    Contact: Karen Blatter, 815-227-2676,

General Treatment Studies

  • A221602: Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial

  • Summary: This randomized phase III trial studies how well olanzapine with or without fosaprepitant work in preventing chemotherapy induced nausea and vomiting in cancer patients receiving chemotherapy that causes vomiting. Olanzapine and fosaprepitant dimeglumine may help control nausea and vomiting in patients during chemotherapy. Olanzapine is usually given in combination with other drugs, including fosaprepitant dimeglumine. It is not yet known if olanzapine when given with other drugs, is still effective without using fosaprepitant dimeglumine for controlling nausea and vomiting.

    Investigator: Shylendra Sreenivasappa, MD

    Location: OSF HealthCare Saint Anthony Medical Center, Center for Cancer Care, Rockford, Illinois

    ClinicalTrials.gov:  NCT03578081

    Contact: Karen Blatter, 815-227-2676,

Non-Interventional

  • Synergism of EGFR and c-MET pathways: their therapeutic role in lung cancer

  • Summary: The purpose of this trial is to study the synergism of the human growth factor receptor (c-Met) and the endothelial growth factor receptor (EGFR) related to receptor tyrosine kinase inhibitor (RTKI) resistance and prognosis in patients with diagnosed adenocarcinoma of the lungs, to advance scientific understanding of non-small cell lung cancer tumor biology, to identify biomarkers that may help clinicians establish a more accurate prognosis for future patients, and to develop personalized therapy for future patients using targeted chemotherapeutic regimens based on individual tumor biomarker profiles. This study involves the analysis of previously collected tumor tissue specimens. Patients will be asked to authorize the use of excess tissue remaining from a routine biopsy. No additional biopsy or intervention is required.

    Investigator: Shylendra Sreenivasappa, MD

    Location: OSF HealthCare Saint Anthony Medical Center, Center for Cancer Care, Rockford, Illinois

    Contact: Karen Blatter, 815-227-2676,

  • SEERPRO: A Prospective Blood Sample Collection Study to Evaluate a Panel of Protein-based Biomarkers

  • Summary: This study will compare molecular profiles in the blood of cancer patients versus control groups, which include associated or confounding comorbidities for some cancer types plus healthy controls. The blood samples from these groups will be profiled using the Seer platform to identify, facilitate and expedite the development of future assays. These assays could result in improvements in the screening, treatment, surveillance, and/or additional monitoring of patients with those diseases.

    Investigator: Shylendra Sreenivasappa, MD

    Location: OSF HealthCare Saint Anthony Medical Center, Center for Cancer Care, Rockford, Illinois

    Contact: Karen Blatter, 815-227-2676,

  • TCTP Expression Analysis in Paraffin Embedded and Primary Prostate Cancer Tissue Samples

  • Summary: Prostate cancer tissue will be studied to determine whether the Translationally Controlled Tumor Protein (TCTP) gene can be used as a biomarker for castration-resistant prostate cancer (CRPC). This study involves the analysis of previously collected tumor tissue specimens. Patients will be asked to authorize the use of excess tissue remaining from a routine biopsy. No additional biopsy or intervention is required

    Investigator: Shylendra Sreenivasappa, MD

    Location: OSF HealthCare Saint Anthony Medical Center, Center for Cancer Care, Rockford, Illinois

    Contact: Karen Blatter, 815-227-2676,

  • Physician Awareness:  Early Detection of Non-Small Lung Cancer Study

  • Summary: The purpose of this study is to identify novel biomarker(s) in blood serum of lung cancer patients which could be used for detection of early stage lung cancer. This study will attempt to develop a blood test which can detect lung cancer biomarkers present in early stages of lung cancer and compare them to biomarkers present in benign tumors. Information from this study may have clinical applications which will improve detection and prognosis of NSCLC patients. This study involves only the collection and analysis of specimens. Patients will be asked to provide one sample of blood and authorize the use of previously collected tissue.

    Investigator: Shylendra Sreenivasappa, MD

    Location: OSF HealthCare Saint Anthony Medical Center, Center for Cancer Care, Rockford, Illinois

    Contact: Karen Blatter, 815-227-2676,